ES2073574T3 - Introduccion de liposomas en el tejido isquemico. - Google Patents

Introduccion de liposomas en el tejido isquemico.

Info

Publication number
ES2073574T3
ES2073574T3 ES90907986T ES90907986T ES2073574T3 ES 2073574 T3 ES2073574 T3 ES 2073574T3 ES 90907986 T ES90907986 T ES 90907986T ES 90907986 T ES90907986 T ES 90907986T ES 2073574 T3 ES2073574 T3 ES 2073574T3
Authority
ES
Spain
Prior art keywords
liposomes
introduction
ischemic tissue
nanometers
absence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90907986T
Other languages
English (en)
Inventor
John D Baldeschwieler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexstar Pharmaceuticals Inc
Original Assignee
Vestar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vestar Inc filed Critical Vestar Inc
Application granted granted Critical
Publication of ES2073574T3 publication Critical patent/ES2073574T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/806—Virus-based particle with exterior chemical attachment
    • Y10S977/808—Exterior attachment for targeting, e.g. drug targeting
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE EN GENERAL AL CAMPO DE LA BIOQUIMICA Y DE LA MEDICINA Y DE MANERA MAS PARTICULAR AL USO DE LIPOSOMAS EN EL TRATAMIENTO Y DIAGNOSTICO DE TEJIDOS ISQUEMICOS. LOS LIPOSOMAS DE UN TAMAÑO MENOR DE 200 NANOMETROS ELIGEN COMO BLANCO EL TEJIDO ISQUEMICO Y SUMINISTRAN PREFERIBLEMENTE AGENTES ACTIVOS A LAS ZONAS ENGORGEADAS EN AUSENCIA DE ANTICUERPOS LIGADOS A LOS LIPOSOMAS PARA LLEVAR A CABO EL SUMINISTRO.
ES90907986T 1989-04-18 1990-04-13 Introduccion de liposomas en el tejido isquemico. Expired - Lifetime ES2073574T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33968289A 1989-04-18 1989-04-18
US41171689A 1989-09-25 1989-09-25

Publications (1)

Publication Number Publication Date
ES2073574T3 true ES2073574T3 (es) 1995-08-16

Family

ID=26991750

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90907986T Expired - Lifetime ES2073574T3 (es) 1989-04-18 1990-04-13 Introduccion de liposomas en el tejido isquemico.

Country Status (9)

Country Link
US (1) US5527538A (es)
EP (1) EP0469082B1 (es)
JP (1) JP3010500B2 (es)
AT (1) ATE120640T1 (es)
AU (1) AU639925B2 (es)
DE (1) DE69018460T2 (es)
DK (1) DK0469082T3 (es)
ES (1) ES2073574T3 (es)
WO (1) WO1990012595A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US6312719B1 (en) * 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6773719B2 (en) 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
DE4430592A1 (de) * 1994-08-20 1996-02-22 Max Delbrueck Centrum Liposomale Zubereitung, ihre Herstellung und ihre Verwendung
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
JP4058775B2 (ja) * 1996-06-26 2008-03-12 ザ ウィタカー コーポレーション 電気コネクタ
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6689485B2 (en) * 1997-01-17 2004-02-10 The Penn State Research Foundation Powerful reductant for decontamination of groundwater and surface streams
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
AU2002337770B2 (en) * 2001-09-28 2007-11-08 Esperion Therapeutics, Inc. Methods and apparatus for extrusion of vesicles at high pressure
CA2471967A1 (en) * 2002-01-03 2003-07-31 Board Of Regents, The University Of Texas System Wt1 antisense oligos for the inhibition of breast cancer
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
US20050058698A1 (en) * 2002-01-21 2005-03-17 Nolan Yvonne Mairead Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
WO2004074314A2 (en) * 2003-02-14 2004-09-02 University Of South Florida Chistosan-microparticles for ifn gene delivery
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
WO2008114513A1 (ja) * 2007-03-20 2008-09-25 Osaka University 心筋梗塞の予防および／または治療薬
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873088A (en) * 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4728575A (en) * 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
DE3515335C2 (de) * 1985-04-27 1995-01-26 Bayer Ag Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung
WO1988007851A1 (en) * 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Liposome entrapped n-methyl-d-aspartate receptor blockers
JPH0262829A (ja) * 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤

Also Published As

Publication number Publication date
AU639925B2 (en) 1993-08-12
EP0469082A1 (en) 1992-02-05
EP0469082A4 (en) 1992-06-17
ATE120640T1 (de) 1995-04-15
EP0469082B1 (en) 1995-04-05
JP3010500B2 (ja) 2000-02-21
JPH04507090A (ja) 1992-12-10
DE69018460T2 (de) 1995-11-09
US5527538A (en) 1996-06-18
AU5543490A (en) 1990-11-16
WO1990012595A1 (en) 1990-11-01
DE69018460D1 (de) 1995-05-11
DK0469082T3 (da) 1995-08-28

Similar Documents

Publication Publication Date Title
ES2073574T3 (es) Introduccion de liposomas en el tejido isquemico.
ES2013129A6 (es) Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.
ATE76296T1 (de) Pharmazeutische zusammensetzung zur behandlung von akuter myocardischer ischaemie.
BR1100309A (pt) Peptìdeo e composição farmacêutica para promover a liberação de nìveis de hormÈnio de crescimento em animais
ATE245662T1 (de) Avidin-biotin immunokonjugate
ATE109971T1 (de) Verabreichung von arzneimitteln über die lungen.
IT1232243B (it) Composizioni farmaceutiche a base di ciclosporine
DK0859596T3 (da) Vækstfaktorholdige gelformuleringer
DE69001876T2 (de) Hoch-resorbierbare transvaginale Zubereitung mit biologisch aktiven Peptiden.
IL76932A0 (en) Pharmaceutical compositions containing dihydrocodeine and ibuprofen
FR2784294B1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
IT8050466A0 (it) Composizione ad attivita' ormonica a base di complessi con destrine eprocedimento per prepararne l'ingre diente attivo
NO993866L (no) Legemiddel mot lymfatiske tumorer
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
EP0353474A3 (en) Glycerin derivative and its pharmacological use
CA2051439A1 (en) Liposomal targeting of ischemic tissue
FR2549835B1 (fr) Acides peneme-carboxyliques, leur preparation et leur utilisation therapeutique, notamment en tant qu'agents antibacteriens
IT1249060B (it) Composizione farmaceutica ad uso topico per il trattamento di cicatrizzazione e riepitelizzazione di ulcere flebostatiche croniche.
IT8820984A0 (it) Impiego di un agonista colinergico e di ormone che stimola il rilascio dell'ormone della crescita per la preparazionedi composizioni farmaceutiche aventi utilita' nella diagnosi differenziale della carenza somatotropa.
GB8911638D0 (en) Biologically and therapeutically active agents against hiv-1
ATA71491A (de) Pharmakologisch aktive in position 3 substituierte alpha-aminomethyl-2benzofuranmethanole
GB8719227D0 (en) Biologically & therapeutically active agents
ITBS920131A1 (it) Macchina per preparare e distribuire malte, intonaci e materiali pastosi per l'edilizia in genere

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 469082

Country of ref document: ES